Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC)

Adv Exp Med Biol. 1998:431:657-60. doi: 10.1007/978-1-4615-5381-6_127.

Authors

J R Kroep¹, C J van Moorsel, G Veerman, D A Voorn, R M Schultz, J F Worzalla, L R Tanzer, R L Merriman, H M Pinedo, G J Peters

Affiliation

¹ Department of Med. Oncology, University Hospital VU, Amsterdam, The Netherlands.

PMID: 9598147
DOI: 10.1007/978-1-4615-5381-6_127

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antimetabolites, Antineoplastic / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / enzymology*
Cytidine Deaminase
Deoxycytidine / analogs & derivatives*
Deoxycytidine / therapeutic use
Deoxycytidine Kinase / metabolism*
Drug Resistance, Neoplasm
Gemcitabine
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / enzymology*
Mice
Nucleoside Deaminases / metabolism*
Pancreatic Neoplasms / drug therapy
Pancreatic Neoplasms / enzymology*
Thymidine Kinase / metabolism*
Transplantation, Heterologous

Substances

Antimetabolites, Antineoplastic
Deoxycytidine
thymidine kinase 2
Thymidine Kinase
Deoxycytidine Kinase
Nucleoside Deaminases
Cytidine Deaminase
deoxycytidine deaminase
Gemcitabine